Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine

J Clin Endocrinol Metab. 1987 Mar;64(3):447-53. doi: 10.1210/jcem-64-3-447.

Abstract

We studied the effects of acute and chronic sc administration of SMS 201-995 (SMS), a long-acting somatostatin analog, in acromegalic patients. The results were compared with those obtained in the same patients treated with oral bromocriptine (Brc). A single dose of 50 micrograms SMS administered to 28 patients induced a more rapid, greater, and more prolonged reduction in plasma GH levels than did 2.5 mg Brc. Chronic treatment [60-330 days; mean 208 +/- 23 (+/- SEM)] with SMS (100-300 micrograms/day) induced in 16 patients a significantly greater decrease in mean plasma GH and somatomedin-C levels than did 20 mg Brc. Combined treatment with the 2 agents had an additional effect. The clinical and metabolic parameters of acromegaly dramatically improved in all patients whose plasma GH and somatomedin-C levels decreased even if they were not normalized by SMS. Reduction in tumor size occurred in 3 of the 10 patients examined by computed tomography before and during SMS treatment. We conclude that SMS is more effective than Brc and that the 2 drugs may be complementary in the medical treatment of acromegaly.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acromegaly / blood
  • Acromegaly / drug therapy*
  • Adult
  • Aged
  • Bromocriptine / therapeutic use*
  • Female
  • Growth Hormone / blood
  • Growth Hormone-Releasing Hormone
  • Humans
  • Insulin-Like Growth Factor I / blood
  • Male
  • Middle Aged
  • Octreotide
  • Somatostatin / analogs & derivatives*
  • Somatostatin / therapeutic use

Substances

  • Bromocriptine
  • Somatostatin
  • Insulin-Like Growth Factor I
  • Growth Hormone
  • Growth Hormone-Releasing Hormone
  • Octreotide